



(11) **EP 3 416 624 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
23.08.2023 Bulletin 2023/34

(45) Date of publication and mention
of the grant of the patent:
19.07.2023 Bulletin 2023/29

(21) Application number: **17754041.6**

(22) Date of filing: **21.02.2017**

(51) International Patent Classification (IPC):
A61K 9/14 ^(2006.01) **A61K 9/51** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61K 9/5153; A61K 9/19; A61K 9/51;
A61K 9/5146; A61K 9/5192; A61K 47/26

(86) International application number:
PCT/US2017/018743

(87) International publication number:
WO 2017/143346 (24.08.2017 Gazette 2017/34)

(54) **PROCESS FOR THE PREPARATION OF TOLERIZING IMMUNE-MODULATING PARTICLES**

VERFAHREN ZUR HERSTELLUNG VON TOLERIERENDEN IMMUNMODULIERENDEN
PARTIKELN

PROCÉDÉ DE PRÉPARATION DE PARTICULES IMMUNOMODULATRICES INDUISANT UNE
TOLÉRANCE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **18.02.2016 US 201662296840 P**

(43) Date of publication of application:
26.12.2018 Bulletin 2018/52

(60) Divisional application:
23185616.2

(73) Proprietor: **Cour Pharmaceuticals Development**
Company Inc.
Skokie, IL 60077 (US)

(72) Inventors:
• **GETTS, Daniel R.**
Northbrook
Illinois 60062 (US)
• **FOKTA, Frank**
Northbrook
Illinois 60062 (US)

• **PEARSON, Ryan**
Northbrook
Illinois 60062 (US)

(74) Representative: **CMS Cameron McKenna Nabarro**
Olswang LLP
Cannon Place
78 Cannon Street
London EC4N 6AF (GB)

(56) References cited:
WO-A1-2014/169255 WO-A2-2015/023796
US-A- 4 574 058 US-A1- 2015 010 631
US-A1- 2015 297 531

• **JUNG, KA ET AL.: 'Cardiovascular Protective**
Properties of Kiwifruit Extracts in Vitro'
BIOLOGICAL AND PHARMACEUTICAL
BULLETIN vol. 28, no. 9, 2005, pages 1782 - 1785,
XP009156175
• **KIM, S.: 'Production of composites by using**
gliadin as a bonding materia' JOURNAL OF
CEREAL SCIENCE vol. 54, 2011, pages 168 - 172,
XP028248398

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 416 624 B8